The peptide cannot be obtained through normal pharmaceutical channels
Total 180 capsules
Disclosure of interest: Isehaq Al jabri: nothing to disclose E-Posters - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.07 - SMALL VESSEL DISEASE P2408 - ESOC25-2000 CERERBAL AMYLOID ANGIOPATHY AND AMYLOID LOAD DISTRIBUTION DETECTED ON AMYLOIDPOSITRON EMISSION TOMOGRAPHY: A SYSTEMATIC REVIEW AND META-ANALYSIS Aikaterini Theodorou 1 , Konstantinos Melanis 1 , Athanasia Athanasaki 1 , Eleni Bakola 1 , Maria Chondrogianni 1 , Vasiliki Kotsali-Peteinelli 1 , Georgia Papagiannopoulou 1 , Anna Keramida 1 , Efthimios Vasilopoulos 2 , Anastasios Kouzoupis 2 , Georgios Velonakis 3 , Foteini Boufidou 4 , George Paraskevas 1 , Ilias Tzavellas 2 , Georgios Tsivgoulis 1 1 Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 2 First Department of Psychiatry, Aiginition Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 3 Second Department of Radiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 4 First Department of Neurology, "Eginition" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece Background and Aims: There are limited data regarding the amyloid positron emission tomography (PET) imaging among patients with Cerebral Amyloid Angiopathy (CAA)
Penta deca peptide arginate, with its distinct formulation and nomenclature, remains available through licensed healthcare providers, making it the more accessible option for researchers working within legal frameworks
Kota et al
